10-Q: NewAmsterdam Pharma Reports Reduced Loss, Positive AD Data

NewAmsterdam Pharma reported a significant reduction in net loss for Q2 2025, driven by increased license revenue and decreased R&D expenses, alongside positive Alzheimer's disease biomarker data for obicetrapib.

Summary

• Net loss for the three months ended June 30, 2025, significantly decreased to $17.4 million from $39.0 million in the prior year period.
• Revenue for the three months ended June 30, 2025, surged to $19.1 million, a 740% increase from $2.3 million in the prior year, primarily due to a $16.1 million recognition from the Menarini License.
• Research and development expenses decreased by 28% to $27.5 million in Q2 2025, mainly due to the completion of several Phase 3 clinical trials.
• Selling, general and administrative expenses increased by 65% to $27.3 million in Q2 2025, driven by personnel costs and commercial preparedness activities.
• Cash, cash equivalents, and marketable securities totaled $783.3 million as of June 30, 2025.
• Positive data from the prespecified Alzheimer's Disease biomarker analysis in the BROADWAY clinical trial showed obicetrapib significantly lowered plasma p-tau217, a key AD biomarker, in patients with ASCVD and/or HeFH.
• The earnout milestone triggering event occurred in March 2025, leading to the issuance of 1,743,136 Ordinary Shares and full settlement of the derivative earnout liability.

Sentiment

Score: 7

Explanation: The company demonstrated strong financial improvements with reduced losses and increased license revenue. The positive Alzheimer's disease biomarker data for obicetrapib is a significant and potentially transformative development, opening a new large market opportunity. While still pre-revenue and incurring losses, the strong cash position provides a solid runway for continued development. The risks are typical for a biopharma at this stage, but the new AD data adds considerable upside potential.

Positives

• Significant reduction in net loss for both the three-month ($21.6 million decrease) and six-month ($75.9 million decrease) periods ended June 30, 2025, indicating improved financial performance.
• Substantial increase in revenue, primarily from the Menarini License, with $16.1 million recognized from development cost contributions, demonstrating successful monetization of intellectual property.
• Positive Alzheimer's Disease biomarker data from the BROADWAY trial, showing statistically significant reductions in plasma p-tau217 (p=0.0019 for full analysis set, p=0.0215 for ApoE4 carriers), potentially expanding obicetrapib's therapeutic scope beyond cardiometabolic diseases into a high-value area.
• Strong liquidity position with $783.3 million in cash, cash equivalents, and marketable securities as of June 30, 2025, providing a solid financial runway for ongoing operations and development.
• Completion of several Phase 3 clinical trials in the second half of 2024 led to a decrease in R&D expenses, reflecting progress in the development pipeline and cost management.
• Achievement and full settlement of the earnout milestone in March 2025, fulfilling a contractual obligation and demonstrating progress on prior agreements.

Negatives

• Continued operating losses, with a loss of $17.4 million for Q2 2025 and $56.9 million for the six months ended June 30, 2025, as the company remains pre-commercial.
• Significant increase in selling, general and administrative expenses (65% for Q2, 76% for six months), driven by public company costs and commercial preparedness, indicating rising overhead.
• Net cash used in investing activities increased substantially to $156.3 million for the six months ended June 30, 2025, primarily due to purchases of available-for-sale debt securities, reducing overall cash balance.
• Net cash provided by financing activities decreased significantly to $9.9 million for the six months ended June 30, 2025, compared to $202.8 million in the prior year, reflecting the absence of large follow-on offerings.
• The company has not yet generated revenue from product sales and expects to incur significant losses for the foreseeable future, highlighting continued reliance on financing and license agreements.

Risks

• Dependence on the success of obicetrapib, including obtaining regulatory approval, which requires significant additional research and development efforts and capital.
• Uncertainty regarding when, if ever, significant revenue from product sales will be realized.
• Ability to attract and retain senior management and key scientific personnel.
• Limited experience in marketing or distributing products.
• Risks related to international operations.
• Ability to achieve broad physician adoption and market acceptance for commercial success.
• Estimates regarding expenses, future revenue, capital requirements, and needs for additional financing may prove inaccurate.
• Impact of government laws and regulations, including potential adverse effects from changes in U.S. government policies and increased tariffs (e.g., 10% baseline tariff imposed in April 2025), which could raise production costs and disrupt supply chains.
• Reliance on third parties for all aspects of manufacturing product candidates for clinical trials.
• Efforts to obtain, protect, or enforce patents and other intellectual property rights related to product candidates.
• The exercise of outstanding warrants is highly dependent on the company's Ordinary Share price, and there is no assurance that they will be 'in the money' prior to expiration, potentially yielding little to no additional cash proceeds.

Future Outlook

The company expects to continue incurring significant losses as it invests in clinical and preclinical development programs. Future revenue from potential collaborations is uncertain and dependent on successful development and regulatory approval of obicetrapib. The company aims to commercialize obicetrapib in the United States independently and seek additional partners for other jurisdictions, while also evaluating potential acquisitions or licenses of new product candidates.

Management Comments

• We are a late-stage biopharmaceutical company whose mission is to improve patient care in populations with cardiometabolic diseases where currently approved therapies have not been adequate or well tolerated.
• We believe that obicetrapib has the potential to be a once-daily oral CETP inhibitor for lowering LDL-C, if approved.
• We have observed obicetrapib to be well tolerated in an aggregate of over 3,500 patients with low or moderately elevated LDL-C levels (dyslipidemia) in our clinical trials to date.
• Our goal is to develop and commercialize an LDL-C lowering monotherapy and a fixed-dose combination therapy, which offers the advantage of a single, low dose, once-daily oral pill, and fulfills the significant unmet need for an effective and convenient LDL-C lowering therapy.
• We do not expect to generate any revenue from product sales for the foreseeable future.
• We expect our research and development expenses to be significant as we advance our product candidates through clinical trials and pursue regulatory approval.
• Due to the general growth of the organization associated with administering ongoing and planned clinical trials and our focus on commercial preparedness, we expect that our selling, general and administrative expenses may increase.

Industry Context

NewAmsterdam Pharma operates in the highly competitive biopharmaceutical industry, specifically targeting cardiometabolic diseases and now potentially Alzheimer's disease. The company's focus on obicetrapib, a CETP inhibitor, positions it against existing lipid-lowering therapies like statins and injectables, aiming to address unmet needs for oral, well-tolerated options. The positive Alzheimer's biomarker data is a significant development, potentially opening a new, large market for obicetrapib, aligning with broader industry trends of exploring multi-indication potential for drug candidates and addressing neurodegenerative diseases.

Comparison to Industry Standards

• Obicetrapib's demonstrated LDL-C lowering efficacy and safety profile comparable to placebo in multiple Phase 3 trials (BROADWAY, BROOKLYN, TANDEM) and Phase 2 trials (TULIP, ROSE, OCEAN, ROSE2, Japan Phase 2b) positions it favorably against existing therapies that may have limited efficacy or tolerability issues.
• The 21% reduction in exploratory MACE endpoint observed in the BROADWAY trial for obicetrapib aligns with the MACE benefit seen in trials of other LDL-C lowering drugs, such as anacetrapib in the REVEAL trial, suggesting a similar mechanism of cardiovascular risk reduction.
• The positive Alzheimer's disease biomarker data (reduction in plasma p-tau217) from the BROADWAY trial builds on previous Phase 2a proof-of-concept and preclinical data, suggesting a potential for obicetrapib in neurodegenerative diseases, a field where many drug candidates have failed, making this a notable finding.
• The company's strategy to pursue commercialization in the U.S. independently while partnering with Menarini for Europe (exclusive rights) is a common hybrid model for biopharma companies, balancing direct market access with leveraging established regional sales networks.
• The preference for oral drugs over injectable therapies (estimated over 75% of ASCVD and HeFH outpatients) highlights obicetrapib's potential market advantage if approved as a once-daily oral pill, addressing a key patient preference in the lipid-lowering market.

Corporate Governance

Legal Proceedings

• Not party to any material pending legal proceedings.

Related Party Transactions

• Transactions with related parties were reviewed quarterly and have not been material to the consolidated financial statements.

Stakeholder Impact

• Shareholders: Potential for increased value due to positive clinical data and progress towards commercialization, but also continued dilution risk from potential future capital raises and warrant exercises.
• Employees: Increased recruitment and employment costs for administrative and commercial preparedness activities, indicating growth opportunities. Share-based compensation plans are in place.
• Customers (future): Potential for a new, effective, and convenient oral therapy for cardiometabolic diseases and potentially Alzheimer's disease.
• Creditors: Strong cash position ($783.3 million) provides financial stability.
• Suppliers/CROs/CMOs: Continued engagement for preclinical, clinical development, and manufacturing services, with estimated maximum cancellation fees of $20.5 million.

Next Steps

• Continue advancing obicetrapib through clinical trials towards regulatory approval.
• Prepare and submit regulatory applications for obicetrapib.
• Pursue commercialization of obicetrapib in the United States independently, if approved.
• Consider additional partners for jurisdictions outside of the United States and the European Union, including Japan and China.
• Continually evaluate the potential acquisition or license of new product candidates.
• Conduct the Phase 3 cardiovascular outcomes trial (CVOT), PREVAIL, to reconfirm MACE benefit.

Key Dates

Recommendation

The significant reduction in net loss, coupled with a substantial increase in license revenue, indicates improving financial health. Crucially, the positive Alzheimer's disease biomarker data for obicetrapib from the BROADWAY trial represents a major potential upside, opening a new, high-value therapeutic area beyond its primary cardiometabolic focus. The company maintains a robust cash position of $783.3 million, providing ample runway for continued development and commercialization efforts. While still pre-revenue from product sales and facing typical biopharma development risks, the expanded market potential and solid financial footing make this an attractive long-term investment.

Keywords

Biopharmaceutical, Cardiometabolic Disease, LDL-C, Obicetrapib, CETP Inhibitor, Alzheimer's Disease, Clinical Trials, Phase 3, Drug Development, SEC Filing, 10-Q, Financial Results, Biomarker, ApoE4, p-tau217, Menarini License, Nasdaq